Johnson & Johnson (JNJ)
| Market Cap | 500.07B |
| Revenue (ttm) | 92.15B |
| Net Income (ttm) | 25.12B |
| Shares Out | 2.41B |
| EPS (ttm) | 10.35 |
| PE Ratio | 20.06 |
| Forward PE | 18.61 |
| Dividend | $5.20 (2.51%) |
| Ex-Dividend Date | Nov 25, 2025 |
| Volume | 6,728,846 |
| Open | 206.49 |
| Previous Close | 206.67 |
| Day's Range | 205.94 - 207.81 |
| 52-Week Range | 140.68 - 207.81 |
| Beta | 0.36 |
| Analysts | Buy |
| Price Target | 196.60 (-5.28%) |
| Earnings Date | Oct 14, 2025 |
About JNJ
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizo... [Read more]
Financial Performance
In 2024, Johnson & Johnson's revenue was $88.82 billion, an increase of 4.30% compared to the previous year's $85.16 billion. Earnings were $14.07 billion, a decrease of -59.99%.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price target is $196.6, which is a decrease of -5.28% from the latest price.
News
3 Superb Dividend Stocks to Hold for the Next 20 Years
Johnson & Johnson is a financial fortress with a solid pipeline and portfolio. Coca-Cola has an asset-light model that drives its profitability.
Have $2,000 to Invest? Here Are 4 of My Favorite Dividend Stocks for the Next 5 Years
Pfizer and Johnson & Johnson are healthcare leaders and faithful dividend payers. Home Depot is facing a difficult operating environment, but its core business remains strong.
JNJ Stock vs. PFE Stock: Which Pharmaceutical Giant Is A Better Buy?
The pharmaceutical powerhouse Johnson & Johnson (NYSE: JNJ) has significantly outperformed its competitor Pfizer (NYSE: PFE) this year. JNJ's stock has risen by almost 45%, whereas PFE has declined by...
1 Reason Why Shares of Johnson & Johnson Are Surging This Month
Last month, Johnson & Johnson surged following a well-received quarterly earnings release. Despite a sluggish start to November, a spate of positive news has since sent the healthcare stock's shares t...
Why Johnson & Johnson's Share Price Is Popping This Month
J&J beat Wall Street estimates on sales and profits in the third quarter. The company recently announced the acquisition of a biotech with an innovative cancer treatment.
Vida Ventures Marks Fourth Major Portfolio Acquisition in 2025, Capping a Record-Setting Year for Its Science-Led, Discipline-Driven Strategy
LOS ANGELES & BOSTON--(BUSINESS WIRE)--Vida Ventures (“Vida”), a next-generation life sciences venture firm, today announced its fourth major Vida portfolio acquisition of 2025, capping an unprecedent...
Johnson & Johnson (JNJ) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript
Johnson & Johnson ( JNJ) 7th Annual Wolfe Research Healthcare Conference November 17, 2025 10:40 AM EST Company Participants Candice Long - Worldwide Vice President of Immunology David Lee - Global T...
Johnson & Johnson to Buy Halda Therapeutics For $3.05 Billion
Johnson & Johnson has agreed to buy clinical-stage biotechnology company Halda Therapeutics for $3.05 billion in cash in a deal that bolsters the healthcare giant's oncology pipeline.
Halda Therapeutics Announces Acquisition by Johnson & Johnson
NEW HAVEN, Conn., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Halda Therapeutics announced today that it has entered into a definitive agreement pursuant to which Johnson & Johnson will acquire Halda for $3.05 ...
J&J to buy cancer therapy developer Halda Therapeutics for $3.05 billion
Johnson & Johnson said on Monday it would buy Halda Therapeutics for $3.05 billion in cash, expanding its presence in solid tumors and prostate cancer treatments.
New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis
First-line treatment with TREMFYA® shows significant inhibition of radiographic progression at Week 24, which was sustained through Week 48, preserving joint health with a well-established safety prof...
Johnson & Johnson Set to Revolutionize the Treatment of Cancer With the Acquisition of Halda Therapeutics
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced today that it has entered into a definitive agreement to acquire Halda Therapeutics OpCo, Inc. (Halda), a clinical-stage b...
Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman
Evan Seigerman, BMO Capital Markets head of health care research, joins 'Power Lunch' to discuss what's behind the recent move in health care stocks, the state of play with GLP-1s and much more.
Bristol Myers, J&J halt heart drug trial after interim review
Bristol Myers Squibb and Johnson & Johnson said on Friday they would stop a late-stage trial of their experimental blood clot drug in heart attack patients, after an independent review found the study...
2 Healthcare Stocks for Beginner Investors With a 40-Year Time Horizon
These companies are leaders in their respective industries and are both very profitable. Intuitive Surgical has been the dominant presence in the surgical robotics market for decades.
2 Strong Healthcare Stock Picks for Dividend Investors
These companies have exceptional dividend track records. AbbVie is moving on from its Humira patent losses, and its portfolio benefits from some exceptionally profitable products.
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever.
CVS Health is successfully navigating industrywide and company-specific headwinds while maintaining a solid dividend program. Johnson & Johnson's rock-solid balance sheet and ability to develop brand-...
Johnson & Johnson (JNJ) Presents at UBS Global Healthcare Conference 2025 Transcript
Johnson & Johnson ( JNJ) UBS Global Healthcare Conference 2025 November 11, 2025 11:00 AM EST Company Participants Peter Menziuso Conference Call Participants Danielle Antalffy - UBS Investment Bank,...
Johnson & Johnson (JNJ) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript
Johnson & Johnson ( JNJ) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 11, 2025 10:30 AM EST Company Participants Sarah Brennan Mark Wildgust Conference Call Participants...
Johnson & Johnson: 2 Recent FDA Wins And Earnings Beat Warrant 'Buy' Rating
Johnson & Johnson remains a "buy" following strong Q3 2025 results, driven by robust sales growth and raised full-year 2025 revenue guidance. The company's acquisition of Intra-Cellular Therapies and ...
FDA Clears Johnson & Johnson's Darzalex Faspro, Enabling Early Intervention In Myeloma Progression
The U.S. Food and Drug Administration (FDA) approved on Thursday Johnson & Johnson's (NYSE:JNJ) Darzalex Faspro (daratumumab and hyaluronidase-fihj) for a type of blood cancer.
Johnson & Johnson: Dividends Don't Lie
Johnson & Johnson's latest dividend declaration translates into an annual growth rate of 4.47%. This is the lowest level in at least 10 years, signaling ongoing growth pressures. Mixed Q3 earnings res...